stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.10
0.17
−3.23%
Follow RGC
Alert me
| Jun '26 | Dec '25 | Jun '25 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
10.77 | 1.42 | 7.38 | 41.91 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | (1.97) | (0.02) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (2.59) | (3.27) | (4.01) | |
Working Capital |
12.90 | 0.69 | 4.24 | 7.92 | |
Capital Expenditures |
— | — | (0.15) | (0.01) | |
Net Current Asset Value |
12.84 | 0.56 | 4.01 | 7.89 | |
| Other line items | |||||
Quick Ratio |
10.74 | 1.42 | 7.38 | 41.12 | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Average Assets |
13.68 | 9.28 | 11.89 | 14.75 | |
Average Common Equity |
12.67 | 7.95 | 10.97 | 13.96 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026